Imagion Biosystems Limited (Company) is committed to the objective of promoting investor confidence and the rights of shareholders.
Read the Imagion Biosystems Limited Disclosure and Communication Policy.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal